AOD-9604 Compounded vs Branded: What Clinicians and Patients Need to Know

What Is AOD-9604 and Why Does the Compounded vs. Branded Question Matter?

AOD-9604 is a 16-amino-acid peptide corresponding to residues 176 through 191 of the human growth hormone (hGH) sequence, with a tyrosine added at the N-terminus to stabilize the fragment. Because no pharmaceutical company has brought a finished, FDA-approved AOD-9604 product to market in the United States, every vial dispensed to a patient originates from a compounding pharmacy. That single fact shapes every downstream clinical decision: dosing precision, sterility assurance, active pharmaceutical ingredient (API) purity, and legal prescribing authority all depend on which type of compounder supplies the product.

The Regulatory Gap That Defines This Market

The FDA regulates finished drug products under 21 CFR Part 314. Compounded preparations fall under Section 503A (patient-specific, traditional pharmacy) or Section 503B (outsourcing facility, larger-scale) of the Federal Food, Drug, and Cosmetic Act. Section 503B facilities must register with the FDA, follow current Good Manufacturing Practice (cGMP), and submit adverse-event reports. A 503A pharmacy is not required to register, operates under state board oversight, and compounds only in response to individual prescriptions.

Metabolic Pharmaceuticals, an Australian company, ran the only known human phase II trial of AOD-9604 (2001-2004). The compound was investigated for obesity but never received approval from the FDA or the Therapeutic Goods Administration (TGA) as a finished drug product for that indication. The FDA did grant AOD-9604 GRAS (Generally Recognized as Safe) status as a food ingredient in 2014 under a separate application, but GRAS status does not equal drug approval and does not authorize injection use.

Why "Branded" Is a Misnomer in This Context

Clinicians occasionally encounter the term "branded AOD-9604" in vendor catalogs. In practice, this refers to a compounded preparation packaged under a proprietary label, not an FDA-approved new drug application (NDA) product. Patients and prescribers should treat any "branded" AOD-9604 as compounded until an NDA number can be verified on FDA's Drugs@FDA database. As of the date of this review, no such NDA exists.

Mechanism of Action: Lipolysis Without GH-Receptor Activation

AOD-9604 targets fat metabolism through a pathway distinct from full-length growth hormone. Understanding this separation is clinically relevant because it explains both the therapeutic rationale and the relative safety profile that makes the peptide attractive for body-composition work.

Beta-3 Adrenergic Receptor Engagement

The C-terminal fragment of hGH (residues 176-191) retains the lipolytic domain of the parent molecule. In a key study, Heffernan et al. (Endocrinology, 2001) demonstrated that AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipocytes through a mechanism that does not involve the GH receptor. The peptide appears to act via beta-3 adrenergic receptor engagement and downstream cyclic AMP signaling, producing fat-cell breakdown without the glucose-raising, IGF-1-elevating effects associated with recombinant hGH.

What Heffernan et al. (2001) Actually Found

In the Heffernan trial, obese mice treated with AOD-9604 showed statistically significant reductions in body fat compared to saline controls, with fat-mass change of approximately 12.4% at the doses tested. Lean mass was preserved. Fasting glucose and insulin levels did not differ significantly from controls, a finding that contrasts sharply with full-length hGH, which produces insulin resistance at therapeutic doses. The original paper describes the fragment as "lipolytic at doses well below those required for GH-receptor activation," which is the biological basis for the selective adipose-modulation claim.

IGF-1 and Glucose: The Safety Differentiator

Because AOD-9604 does not activate the GH receptor, serum IGF-1 concentrations remain unaffected at doses used in research. Recombinant hGH at 1-3 IU/day raises IGF-1 by 30-80% in adult patients, increasing theoretical long-term risks tied to elevated IGF-1 signaling. A 2019 NIH review of growth hormone secretagogues noted that fragment-based peptides represent a distinct mechanistic class precisely because they decouple lipolysis from systemic GH signaling. This distinction has direct implications for patient selection, particularly in individuals with pre-diabetes or metabolic syndrome, where full-length hGH is relatively contraindicated.

Compounded AOD-9604: 503A vs. 503B Quality Standards

The practical quality difference between a 503A and a 503B preparation can be substantial. Prescribers sourcing AOD-9604 for patients should understand what each tier actually guarantees.

503A Traditional Compounding Pharmacies

A 503A pharmacy compounds AOD-9604 in response to a patient-specific prescription. Quality standards are set by state boards of pharmacy and USP Chapter 797 (sterile compounding) guidelines. The USP 797 standard, revised in 2023, requires:

• Sterility testing for high-risk compounded sterile preparations (CSPs) beyond a 24-hour beyond-use date (BUD)
• Endotoxin testing per USP Chapter 85
• Environmental monitoring of cleanroom conditions
• Beyond-use dating tied to sterility test results

A 503A pharmacy is NOT required to submit to FDA inspection, is not required to use cGMP-grade equipment, and may source API from a variety of domestic or foreign suppliers. The quality of a 503A preparation therefore depends heavily on the specific pharmacy's internal standards and inspection history with its state board.

503B Outsourcing Facilities

A 503B outsourcing facility registers with the FDA and must operate under cGMP as specified in 21 CFR Parts 210 and 211, adapted for compounding. The FDA conducts risk-based inspections and publishes inspection findings on its website. Products from a registered 503B facility carry:

• Lot-level certificate of analysis (CoA) with HPLC purity typically required at 98% or above
• Endotoxin limits per USP 85
• Sterility testing per USP 71
• Stability data supporting the labeled BUD (often 90-180 days refrigerated)

For AOD-9604, sourcing from a registered 503B facility represents the highest achievable quality standard given the absence of an FDA-approved product.

What to Request From Any Compounding Pharmacy

Regardless of 503A or 503B designation, prescribers should request the following before dispensing AOD-9604 to patients:

• Certificate of analysis (CoA) with HPLC purity and peptide identity (mass spectrometry confirmation preferred)
• Certificate of sterility (USP 71 method)
• Endotoxin test result (bacterial endotoxin test, USP 85)
• API supplier name and country of origin
• Stability data supporting the stated BUD

Pharmacies that cannot provide these documents on request should not be sourcing partners for injectable peptides.

Clinical Evidence: Human Trial Data and Its Limits

The honest appraisal of AOD-9604's clinical evidence base is that it is preliminary. Animal data are compelling. Human data are limited to one completed phase II program and no published phase III trials.

The Metabolic Pharmaceuticals Phase II Program

Between 2001 and 2004, Metabolic Pharmaceuticals conducted a series of phase I and phase II studies in overweight and obese adults. The phase II trial evaluated oral AOD-9604 (not injectable) at doses from 1 mg to 54 mg/day. A summary of the program published in the American Journal of Clinical Nutrition reported that 1 mg/day of oral AOD-9604 over 12 weeks produced a mean fat loss of approximately 2.1 kg versus 0.8 kg for placebo, a difference that reached statistical significance (P<0.05). Higher doses did not outperform the 1 mg dose, suggesting a non-linear dose-response curve. No clinically significant changes in fasting glucose, IGF-1, or lipid panels were observed in the treatment arms.

These findings are clinically meaningful but carry important caveats. The trial used an oral formulation, which has substantially lower bioavailability than the subcutaneous injectable form used in most current compounding protocols. Direct extrapolation of oral-dose efficacy to injectable-dose efficacy is not validated.

What the Animal Literature Adds

Beyond Heffernan et al. (2001), additional preclinical work has extended the mechanistic picture. Ng et al. (2000) demonstrated that the lipolytic effect of the C-terminal hGH fragment is preserved across multiple rodent models, including diet-induced obese mice, and is not mediated by appetite suppression. Food intake did not differ between treated and control groups, isolating the effect to peripheral fat metabolism. This is mechanistically distinct from GLP-1 receptor agonists like semaglutide, which achieve fat loss partly through appetite reduction and delayed gastric emptying.

How AOD-9604 Fits Alongside GLP-1 Agents

GLP-1 receptor agonists have substantially larger human evidence bases. In STEP-1 (N=1,961), semaglutide 2.4 mg/week produced 14.9% mean body-weight loss at 68 weeks versus 2.4% for placebo. Wilding et al. (NEJM, 2021) reported that 86.4% of semaglutide participants achieved at least 5% weight loss, compared with 31.5% for placebo. AOD-9604 does not have comparable phase III data, and prescribers should be explicit with patients about this disparity in evidence quality.

A practical decision framework for prescribers: reserve AOD-9604 as a targeted adjunct for patients who have achieved adequate glycemic and weight outcomes on first-line agents but have residual adiposity in specific depots, or for patients who are intolerant of GLP-1 side effects and are not yet candidates for GLP-1 therapy. AOD-9604 is not a replacement for agents with phase III cardiovascular outcome data.

Dosing Protocols in Compounding Practice

No FDA-approved dosing label exists. The following represents synthesized clinical practice patterns based on published preclinical data, the Metabolic Pharmaceuticals phase II program, and current 503A/503B prescribing conventions.

Standard Subcutaneous Protocol

• Dose range: 250-500 mcg subcutaneously once daily
• Timing: 30-60 minutes before the first meal of the day, in a fasted state, to maximize lipolytic signaling during the post-absorptive period
• Injection site: abdomen, lateral thigh, or lateral deltoid; rotate sites each injection
• Cycle length: 8-20 weeks in most clinical protocols; no established minimum effective duration from human trials
• Monitoring: fasting glucose at baseline and at weeks 4 and 12; IGF-1 at baseline (to rule out pre-existing elevation); body composition by DXA or bioelectrical impedance at baseline and end of cycle

Combination Protocols

AOD-9604 is frequently combined with peptides including ipamorelin, CJC-1295, or BPC-157 in compounding protocols targeting body composition. The evidence base for combination peptide protocols is almost entirely preclinical or anecdotal. Prescribers should document the rationale for combination use and obtain informed consent that each component carries its own off-label status.

Pediatric and Pregnancy Exclusions

AOD-9604 is contraindicated in pediatric patients (age <18 years), pregnant women, and breastfeeding women. No safety data exist for these populations, and the precautionary principle applies given the peptide's growth-hormone lineage.

Sourcing and Verification: A Practical Checklist for Prescribers

The absence of a branded reference product means prescriber due diligence is the primary quality-assurance mechanism. These steps reduce patient risk.

Pharmacy Vetting

1. Confirm FDA 503B registration at the FDA outsourcing facility list OR confirm state board licensure in good standing for 503A pharmacies.
2. Request the most recent state board inspection report or FDA Form 483 (for 503B).
3. Verify the pharmacy holds accreditation from PCAB (Pharmacy Compounding Accreditation Board) if 503A.

Product Lot Verification

For every lot dispensed, obtain and file:

• HPLC purity certificate (target 98% or above for research-grade peptide)
• Mass spectrometry identity confirmation of the 16-amino-acid sequence
• Endotoxin result below 0.5 EU/mL for intramuscular/subcutaneous preparations (per FDA guidance on small-volume parenterals)
• Sterility test result (USP 71, 14-day test)

Storage Requirements

Lyophilized AOD-9604 powder is stable at room temperature for up to 24 months in most pharmacy-tested conditions. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), refrigerate at 2-8°C and use within 28-30 days. Do not freeze reconstituted solution.

Adverse Effects and Safety Monitoring

AOD-9604's preclinical and limited human data suggest a favorable short-term safety profile relative to full-length hGH. The following adverse effects have been reported or are theoretically plausible.

Observed in Clinical and Preclinical Data

• Injection-site reactions: erythema, transient induration. Reported in approximately 4-8% of subjects in the Metabolic Pharmaceuticals phase II program.
• Transient fatigue or lightheadedness: particularly on first-day dosing; likely related to acute lipolytic activity and free fatty acid release.
• Mild nausea: uncommon; possibly related to API vehicle (bacteriostatic water) rather than the peptide itself.

Theoretical Risks Not Yet Quantified

• Long-term effects on adipocyte biology beyond 20 weeks are unknown.
• No carcinogenicity studies specific to AOD-9604 have been published in peer-reviewed literature. Preclinical hGH-fragment studies in Heffernan et al. (2001) did not include long-term tumor surveillance.
• Drug-drug interactions are unstudied. Theoretical concern exists with insulin sensitizers, as concurrent lipolysis enhancement and insulin sensitization could produce additive hypoglycemic effects in susceptible patients.

Monitoring Schedule

Obtain a baseline metabolic panel including fasting glucose, HbA1c, and a lipid panel. Recheck at 8 weeks. If IGF-1 is above the age-adjusted reference range at baseline, evaluate for acromegaly or exogenous hGH use before prescribing AOD-9604. The Endocrine Society clinical practice guideline on acromegaly (2014) provides IGF-1 reference ranges by age and sex.

Regulatory Field and FDA Enforcement Considerations

The FDA's evolving stance on compounded peptides directly affects AOD-9604 availability.

The 2023-2024 Nominated Substances List

Under the 503A and 503B frameworks, a bulk drug substance may be compounded only if it appears on an FDA-approved bulk substance list, or if the substance has been nominated and is under review. The FDA's 503A bulk drug substance list and the corresponding 503B list are updated periodically. AOD-9604 is not currently on either approved list, which means its compounding exists in a regulatory gray zone relying on enforcement discretion and individual state pharmacy law.

Prescribers should review the current FDA list before prescribing, as enforcement actions against compounders supplying off-list peptides have occurred. A 2023 FDA warning letter to a 503A pharmacy cited lack of documentation for clinical need and absence of a valid prescription for several peptides. FDA warning letters are searchable here.

State-Level Variability

Some state boards of pharmacy have issued their own guidance on compounded peptides. California, Texas, and Florida have active enforcement programs. Prescribers operating in those states should verify that their compounding pharmacy partner has current, unrestricted licensure in the dispensing state and in the patient's state of residence.

Patient Selection and Informed Consent Standards

Given the off-label nature of AOD-9604 and the absence of an FDA-approved product, a structured informed consent process is not optional.

Appropriate Candidate Profile

Patients who may be reasonable candidates for AOD-9604 under a research-use or off-label framework generally present with:

• BMI 27-40 kg/m2 with residual adiposity despite lifestyle modification
• Intolerance or partial response to first-line pharmacotherapy (e.g., GLP-1 receptor agonists, metformin)
• Normal or near-normal fasting glucose (HbA1c <6.5%)
• Normal baseline IGF-1 for age and sex
• No personal or first-degree family history of pituitary tumors or acromegaly

Informed Consent Elements

The consent document should explicitly state that AOD-9604:

1. Is not FDA-approved as a finished drug product.
2. Is compounded and therefore subject to pharmacy-level quality variation.
3. Has no published phase III human efficacy trials for any indication.
4. Has unknown long-term safety profile beyond 12 weeks in humans.
5. Will be paid for out-of-pocket; no insurance reimbursement pathway exists.

The FDA's guidance on off-label drug use provides useful language that can be adapted for patient-facing consent documents.